• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COVID-19 住院和非住院患者 90 天内静脉血栓栓塞症的发生率和决定因素。

Incidence and determinants of venous thromboembolism over 90 days in hospitalized and nonhospitalized patients with COVID-19.

机构信息

Clinic of Internal Medicine, Østfold Hospital, Grålum, Norway.

Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

出版信息

J Intern Med. 2023 Dec;294(6):721-729. doi: 10.1111/joim.13706. Epub 2023 Jul 30.

DOI:10.1111/joim.13706
PMID:37518983
Abstract

INTRODUCTION

COVID-19 is associated with an increased risk of venous thromboembolism (VTE), but there is great variation among reported incidence rates. Most previous studies have focused on hospitalized patients with COVID-19, and only a few reports are from population-based registries.

METHODS

We studied the 90-day incidence of VTE, associated risk factors and all-cause mortality in hospitalized and nonhospitalized patients with COVID-19 in a nationwide cohort. Data on hospitalizations and outpatient visits were extracted from two national registries with mandatory reporting linked by a unique national identification number carried by all Norwegian residents. We performed Cox proportional hazards regression to determine risk factors for VTE after infection with SARS-CoV-2.

RESULTS

Our study included 30,495 patients with positive SARS-CoV-2 polymerase chain reaction with a mean (SD) age of 41.9 (17.3) years, and 53% were males. Only 2081 (6.8%) were hospitalized. The 90-day incidence of VTE was 0.3% (95% CI: 0.21-0.33) overall and 2.9% (95% CI: 2.3-3.7) in hospitalized patients. Age (hazard ratio [HR] 1.28 per decade, 95% CI: 1.11-1.48, p < 0.05), history of previous VTE (HR 4.69, 95% CI: 2.34-9.40, p < 0.05), and hospitalization for COVID-19 (HR 23.83, 95% CI: 13.48-42.13, p < 0.05) were associated with risk of VTE.

CONCLUSIONS

The 90-day incidence of VTE in hospitalized and nonhospitalized patients with COVID-19 was in the lower end compared with previous reports, with considerably higher rates in hospitalized than nonhospitalized patients. Risk factors for VTE were consistent with previously reported studies.

摘要

简介

COVID-19 与静脉血栓栓塞症(VTE)的风险增加有关,但报告的发病率差异很大。大多数先前的研究都集中在 COVID-19 的住院患者,只有少数报告来自基于人群的登记处。

方法

我们在全国性队列中研究了 COVID-19 住院和非住院患者的 90 天 VTE 发生率、相关危险因素和全因死亡率。从两个具有强制性报告的全国性登记处提取了住院和门诊就诊数据,这些数据通过所有挪威居民持有的唯一国家识别号码进行链接。我们使用 Cox 比例风险回归来确定感染 SARS-CoV-2 后 VTE 的危险因素。

结果

我们的研究包括 30495 例 SARS-CoV-2 聚合酶链反应阳性患者,平均(SD)年龄为 41.9(17.3)岁,53%为男性。只有 2081 例(6.8%)住院。总体而言,90 天 VTE 发生率为 0.3%(95%CI:0.21-0.33),住院患者为 2.9%(95%CI:2.3-3.7)。年龄(每十年的风险比[HR]1.28,95%CI:1.11-1.48,p<0.05)、先前 VTE 史(HR 4.69,95%CI:2.34-9.40,p<0.05)和 COVID-19 住院(HR 23.83,95%CI:13.48-42.13,p<0.05)与 VTE 风险相关。

结论

COVID-19 住院和非住院患者的 90 天 VTE 发生率与先前的报告相比处于较低水平,住院患者的发生率明显高于非住院患者。VTE 的危险因素与先前的研究一致。

相似文献

1
Incidence and determinants of venous thromboembolism over 90 days in hospitalized and nonhospitalized patients with COVID-19.COVID-19 住院和非住院患者 90 天内静脉血栓栓塞症的发生率和决定因素。
J Intern Med. 2023 Dec;294(6):721-729. doi: 10.1111/joim.13706. Epub 2023 Jul 30.
2
Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized With COVID-19.COVID-19 住院患者静脉血栓栓塞症抗凝治疗趋势。
JAMA Netw Open. 2021 Jun 1;4(6):e2111788. doi: 10.1001/jamanetworkopen.2021.11788.
3
Clinical and Genetic Risk Factors for Acute Incident Venous Thromboembolism in Ambulatory Patients With COVID-19.COVID-19 门诊患者急性发作静脉血栓栓塞的临床和遗传危险因素。
JAMA Intern Med. 2022 Oct 1;182(10):1063-1070. doi: 10.1001/jamainternmed.2022.3858.
4
Assessment of the Risk of Venous Thromboembolism in Nonhospitalized Patients With COVID-19.评估非住院 COVID-19 患者的静脉血栓栓塞风险。
JAMA Netw Open. 2023 Mar 1;6(3):e232338. doi: 10.1001/jamanetworkopen.2023.2338.
5
Incidence and clinical profile of venous thromboembolism in hospitalized COVID-19 patients from Madrid region.马德里地区住院COVID-19患者静脉血栓栓塞的发病率及临床特征
Thromb Res. 2021 Jul;203:93-100. doi: 10.1016/j.thromres.2021.05.001. Epub 2021 May 8.
6
Incidence of venous thromboembolism in hospitalized patients with COVID-19.COVID-19 住院患者静脉血栓栓塞症的发生率。
J Thromb Haemost. 2020 Aug;18(8):1995-2002. doi: 10.1111/jth.14888. Epub 2020 Jul 27.
7
Venous Thromboembolism and Major Bleeding in Patients With Coronavirus Disease 2019 (COVID-19): A Nationwide, Population-Based Cohort Study.新型冠状病毒病 2019(COVID-19)患者的静脉血栓栓塞症和大出血:一项全国范围内的基于人群的队列研究。
Clin Infect Dis. 2021 Dec 16;73(12):2283-2293. doi: 10.1093/cid/ciab003.
8
Outcomes in patients discharged with extended venous thromboembolism prophylaxis after hospitalization with COVID-19.COVID-19 住院患者出院后延长静脉血栓栓塞症预防的患者结局。
Vasc Med. 2023 Aug;28(4):331-339. doi: 10.1177/1358863X231159945. Epub 2023 Jun 1.
9
Venous thrombosis, thromboembolism, biomarkers of inflammation, and coagulation in coronavirus disease 2019.2019冠状病毒病中的静脉血栓形成、血栓栓塞、炎症生物标志物及凝血
J Vasc Surg Venous Lymphat Disord. 2021 Jul;9(4):835-844.e4. doi: 10.1016/j.jvsv.2020.11.006. Epub 2020 Nov 12.
10
Clinical characteristics and risk factors for symptomatic venous thromboembolism in hospitalized COVID-19 patients: A multicenter retrospective study.COVID-19 住院患者有症状静脉血栓栓塞的临床特征和危险因素:一项多中心回顾性研究。
J Thromb Haemost. 2021 Apr;19(4):1038-1048. doi: 10.1111/jth.15261. Epub 2021 Feb 24.

引用本文的文献

1
Cardiac events and procedures following COVID-19 compared with other pneumonias: a national register study.与其他肺炎相比,新冠病毒肺炎后的心脏事件和治疗程序:一项全国登记研究。
Open Heart. 2025 Feb 4;12(1):e002914. doi: 10.1136/openhrt-2024-002914.
2
COVID-19 and self-reported health of the Norwegian adult general population: A longitudinal study 3 months before and 9 months into the pandemic.COVID-19 与挪威成年普通人群自报健康状况:大流行前 3 个月和大流行后 9 个月的纵向研究。
PLoS One. 2024 Oct 24;19(10):e0312201. doi: 10.1371/journal.pone.0312201. eCollection 2024.